Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Global E Online Ltd (GLBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Global E Online Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.88 (market cap $29.60B), while Global E Online Ltd trades at $42 (market cap $6.87B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.3× Global E Online Ltd's market cap, and Global E Online Ltd is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GLBE | |
|---|---|---|
Market Cap | $29.60B | $6.87B |
Sector | Health | Technology |
52-Week High | $491.22 | $42.32 |
52-Week Low | $205.48 | $27.54 |
Enterprise Value | $27.56B | $6.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
GLBE trades at $42.08, up 2.26% today and near its 52-week high, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results, beating EPS expectations and raising full-year guidance, driven by 39% revenue growth and expanded EBITDA margins. Analyst consensus is unanimously bullish with a $44.75 price target, reflecting confidence in its e-commerce enablement platform.
The stock offers upside potential from robust growth and strategic acquisitions like Passport, but risks include high valuation multiples (P/E of 61.06) and insider selling. Execution on raised guidance and integration of new logistics capabilities are key to sustaining momentum amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →
